Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

Open Access 31.01.2023 | position paper

Barriers to patient access of CAR T cell therapies in Austria

Chimeric antigen receptor (CAR) T cell therapies offer a promising new therapeutic option for treating B cell malignancies, for instance relapsed or refractory diffuse large B cell lymphoma (DLBCL). However, patient access to this type of cellular …

verfasst von:
Georg Hopfinger, Bernhard Rupp, Richard Greil

24.01.2023 | short review

Update on systemic therapy for clear cell renal cell carcinoma

The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 …

verfasst von:
Dr. Josef Mühlmann

Open Access 19.01.2023 | short review

News on Peripheral T-cell lymphoma

Peripheral T‑cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies. Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV+CHP, anti-CD30) is indicated as first-line treatment in the subgroup anaplastic …

verfasst von:
Dr. Alexander Pichler

Open Access 13.01.2023 | short review

Cutaneous lymphomas—fast facts about an orphan disease—a short review

Cutaneous lymphomas are a rare group of primary skin lymphoproliferative disorders, divided into T and B cell lymphomas. They differ substantially in clinical course and therapy. The two main subtypes of primary cutaneous T‑cell lymphomas include …

verfasst von:
Dr. Stefanie Porkert, Assoc. Prof. PD Dr. Julia Valencak

Open Access 10.01.2023 | short review

Essential news for clinical practice—thyroid cancer

Established systemic treatment options for advanced thyroid cancer include the multityrosine kinase inhibitors lenvatinib and sorafenib for radioactive iodine refractory differentiated thyroid cancer (DTC) and vandetanib and cabozantinib for …

verfasst von:
Barbara Kiesewetter, Ladislaia Wolff, Markus Raderer

05.01.2023 | short review

Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review

Compared to individuals without cancer, patients with a diagnosis of malignancy bear a higher risk of becoming infected with SARS-CoV‑2, suffer more frequently from disease-related complications, and are more likely to die due to coronavirus …

verfasst von:
M.D. Waltraud Elisabeth Huf, M.D. Arschang Valipour

Open Access 03.01.2023 | short review

Dual immune checkpoint blockade in gastroesophageal tumors: never say never

Immunotherapy was proven to be effective as first-line treatment for a subgroup of patients with gastroesophageal tumors and is already established as the standard of care. However, chemotherapy remains the backbone of treatment in both advanced …

verfasst von:
MD PhD Aysegul Ilhan-Mutlu

Open Access 19.12.2022 | short review

Theranostics in prostate cancer

This review summarizes current evidence of “theranostics” for patients with prostate cancer. Prostate-specific membrane antigen (PSMA) is a glycoprotein which can be labeled with positron-emitting tomographic (PET) tracers like fluorine-18 …

verfasst von:
MD, FACNM Rainer W. Lipp

12.12.2022 | short review

Hodgkin lymphoma—how much therapy do we need?

Over the past few decades, cure rates for Hodgkin’s lymphoma (HL) have consistently improved with advances in chemotherapy and radiation treatment. However, these therapies—whilst highly effective—may result in significant long-term toxicity with …

verfasst von:
Barbara Lehner, Michael Panny

Open Access 12.12.2022 | short review

Biomarkers and translational research approaches in breast cancer—an update

Diagnosis and decision-making in the treatment of breast cancer patients is vastly dependent on the exploration of biomarkers. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are long-standing biomarkers …

verfasst von:
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch

30.11.2022 | short review

Total neoadjuvant therapy in rectal cancer

Total neoadjuvant therapy is a novel approach for locally advanced rectal cancer. The optimal treatment sequence is, however, a matter of debate and until now, no overall survival benefit has been reported. This review is a critical, objective …

verfasst von:
MSc Dr. Gudrun Piringer, Prim. Univ.-Doz. Dr. Alexander De Vries

06.10.2022 | review

Dual checkpoint-blockade in urothelial carcinoma—when is it so far

Single agent immunotherapy is routinely used in the treatment of localised and advanced bladder cancer. Dual checkpoint inhibition with nivolumab (nivo)–ipilimumab (ipi) and durvalumab (durva)–tremelimumab (treme) shows encouraging activity in …

verfasst von:
MD Karl Mayrhofer, MD, MBA Dora Niedersüß-Beke

04.07.2022 | comment

Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

verfasst von:
MD, PhD Isabel Heidegger, Andreas Pircher

Open Access 12.04.2022 | short review

Radiotherapy update: current role of radiotherapy in the treatment of lymphomas

Radiotherapy (RT) remains an important modality in the modern treatment of lymphomas. In Hodgkin lymphoma (HL), its role is stage-dependent. In early stage favorable HL, RT is an essential component of combined treatment. In early unfavorable and …

verfasst von:
MD Cora Waldstein

13.10.2020 | original report

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by clonal expansion and accumulation of mature B‑lymphocytes in peripheral blood, bone marrow, and secondary lymphoid tissues [ 1 ]. CLL is highly heterogeneous where some …

verfasst von:
Manal Atef, MD/PhD Layla M. Saleh, Noha Eisa, Sameh Shamaa